Dialog Box

Skin Health Institute

Clinical Trials Now Recruiting

Important COVID-19 Update

In response to the decision made by the Victorian government to place Melbourne Metropolitan area under Stage 4 restrictions, the Skin Health Institute has temporarily suspended recruitment. During this time, we will continue to pre-screen any patients that are interested in participating in a clinical trial. 

Please contact the trials manager Sarah Chivers at schivers@skinhealthinstitute.org.au for further information.


These study descriptions are intended for potential study participants. Study descriptions for clinicians can be found here.  

If you would like to learn more about any of the studies currently being conducted at the Skin Health Institute, please contact the nominated study coordinator.

If you have any general questions regarding the clinical trials conducted at the Institute, please feel free to contact the Clinical Trials Department at trials@skinhealthinstitute.org.au or by phone on (03) 9623 9439.

Hidradenitis Suppurativa Research Trial (71 WEeks)

Adults aged 18 years or older with a diagnosis of hidradenitis suppurativa (HS) for at least 6 months, may qualify to receive investigational medication (active study drug) or placebo, via injection.                           

To be eligible, participants must have HS lesions present in at least 2 distinct areas of the body. Moderate to severe disease with at least 5 inflammatory nodules or abscesses, must be present. Inadequate response to a course of a systemic antibiotic for the treatment of HS, is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 28 times over a period of about 71 weeks. 

For more information, please contact:

Principal Investigator
A/Prof Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Irina Danilovich
9623 9448
idanilovich@skinhealthinstitute.org.au

Research Study for Alopecia areata (26 months)

Adults aged 18 years or older with a clinical diagnosis of alopecia areata (hair loss), may qualify to receive investigational oral medication (active study drug).

To be eligible, participants must have 25% or more hair loss of the scalp, without evidence of terminal hair regrowth within 6 months. Current episode of hair loss must have occurred within 10 years. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.                              

Study participation will last approximately 26 months and involve up to 13 visits to the study centre.                             

For more information, please contact:

Principal Investigator
A/Prof Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Tracy Mallet
9623 9406
tmallett@skinhealthinstitute.org.au


RESEARCH STUDY FOR NAIL FUNGUS (Topical)

Adults aged between 18 and 65 years with onychomycosis (nail fungus), may qualify to receive investigational medication (active study drug) or placebo, via a topical solution that will be brushed on to the infected toe. 

To be eligible, participants must have a fungal toenail infection on at least one big toe, and also be in good health based on past medical history and physical examination as determined by the research doctor at the screening visit. Eligible participants will have regular visits (onsite and phone calls) with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.

Length of study participation will be up to 40 weeks.

For more information, please contact:

Principal Investigator
A/Prof Foley

Sub Investigator
Dr Charlie Wang
9623 9464
cwang@skinhealthinstitute.org.au

Study Coordinator
Sarah Chivers
9623 9465
schivers@skinhealthinstitute.org.au


RESEARCH STUDY FOR ALOPECIA AREATA (32 WEEKS)

Adults aged 18-65 with a clinical diagnosis of alopecia areata with no other cause of hair loss, may qualify to receive investigational oral medication (active study drug) or placebo. 

To be eligible, participants must have ≥ 25% scalp involvement of alopecia, including alopecia totalis (complete scalp hair loss) and alopecia universalis (complete scalp, face and body hair loss).  Duration of the current episode of scalp hair loss must be 6 months to 8 years, with no evidence of terminal hair regrowth within 3 months prior to screening.  Eligible participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 8 times over a period of about 32 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Tracy Mallett
t: 9623 9406
e: tmallett@skinhealthinstitute.org.au


scalp psoriasis research study

Adults 18 years of age or older with a diagnosis of plaque psoriasis for at least 6 months, may qualify to receive investigational medication (active study drug) or placebo via injection.

To be eligible, participants must have moderate to severe plaque psoriasis of the scalp (30% or more of scalp area affected) AND moderate to severe plaque psoriasis of the body (10% or more of body surface area involved). Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 15 times over a period of about 76 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au


HIDRADENITIS SUPPURATIVA RESEARCH STUDY - 1

Adults 18+ years of age with moderate to severe hidradenitis suppurativa (HS) for at least 1 year, may qualify to receive investigational medication (active study drug) or placebo.

To be eligible, participants must have at least 5 inflammatory nodules or abscesses, HS lesions present in at least 2 different areas of the body, and a draining fistula count of 20 or less at the time of study entry. Individuals must also have a history of inadequate response or intolerance to an adequate trial of oral antibiotics for the treatment of HS. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Participation can last up to 85 weeks and involve about 17 visits to the study centre.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au


RESEARCH STUDY FOR HIDRADENITIS SUPPURATIVA - 2

Adults aged 18-75 years old with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least one year, may qualify to receive investigational oral medication (active study drug) or placebo. Participants must agree to use topical antiseptics daily, during study participation.

To be eligible, participants must have HS lesions present in at least 2 distinct areas of the body, with at least 4 inflammatory nodules or abscesses present. Inadequate response to at least a 4-week (28 day) trial of an oral antibiotic for the treatment of HS, is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 10 times over a period of about 26 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au


How do I become involved in a clinical trial at the institute?

Anyone can participate in a clinical trial. A referral from a doctor is not necessary.

Contact the Clinical Trials Department directly to inquire about current research projects to determine your suitability
Phone: (03) 9623 9439
Email: trials@skinhealthinstitute.org.au

Donate